Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Mammalian Cell Banking Market CAGR Outlook And Future Development
The mammalian cell banking market has experienced significant expansion recently. Forecasts indicate it will increase from $3.14 billion in 2025 to $3.5 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.3%. This historical growth can be attributed to monoclonal antibody development, vaccine manufacturing growth, regulatory quality requirements, academic research expansion, and biologics commercialization.
The mammalian cell banking market size is projected to experience substantial expansion over the coming years. Its valuation is anticipated to reach $5.31 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.0%. This projected growth during the forecast period stems from factors such as advancements in gene therapy, the expansion of personalized medicine, the development of biosimilars, robust cell-based therapy pipelines, and the necessity for long-term cell traceability. Key trends anticipated during this period encompass the standardization of cell line preservation methods, the burgeoning of biopharmaceutical pipelines, the proliferation of CGMP-compliant cell banks, a heightened emphasis on genetic stability, and increased reliance on outsourcing to specialized facilities.
Get A Free Sample Report With In-Depth Market Insights:
Mammalian Cell Banking Market Growth Catalysts And Demand Drivers
The mammalian cell banking market is anticipated to experience growth due to the increasing demand for cell-based therapies. These therapies represent advanced medical treatments that employ living cells, frequently modified or engineered, to repair, replace, or regenerate damaged tissues and organs, providing targeted solutions for a broad spectrum of diseases. The surge in demand for cell-based therapies stems from the rising prevalence of chronic and rare diseases, which underscores an urgent requirement for more effective and precise treatment alternatives. Mammalian cell banking supports cell-based therapies by supplying a reliable and standardized source of high-quality cells, thereby guaranteeing consistency, safety, and scalability in the development and manufacturing of regenerative treatments. For instance, in April 2024, according to the American Society of Gene and Cell Therapy, a US-based non-profit medical and scientific organization, the total number of therapies in clinical pipeline phases has increased since the end of 2023, with Phase I demonstrating the most robust growth of 11% since before the fourth quarter of 2022. Consequently, the escalating demand for cell-based therapies is a key driver for the expansion of the mammalian cell banking market.
Mammalian Cell Banking Market Segmentation: How Does The Market Break Down By Category?
The mammalian cell banking market covered in this report is segmented –
1) By Product Type: Master Cell Bank, Working Cell Bank
2) By Cell Type: Chinese Hamster Ovary Mammalian Cell Banking (CHO), Baby Hamster Kidney (BHK), Non-Secreting 0 (NS0), YB2/0 And P2/0, Human Embryonic Kidney 293 (HEK293) And Derivatives, Henrietta Lacks (HELA)
3) By Storage Type: Liquid Nitrogen, Controlled Rate Freezer, Flash Freezing
4) By Application: Drug Development, Vaccine Production, Gene Therapy, Monoclonal Antibody Production
5) By End User: Academic And Research Laboratories, Biopharmaceutical Companies, Contract Research Organizations (CROs)
Subsegments:
1) By Master Cell Bank: Recombinant Cell Lines, Hybridoma Cell Lines, Primary Cell Lines, Genetically Engineered Cell Lines, Viral Vector Producing Cell Lines
2) By Working Cell Bank: Current Good Manufacturing Practice (CGMP)-Compliant Cell Banks, Research-Grade Cell Banks, Clinical Trial Cell Banks, Commercial Production Cell Banks, Stability Testing Cell Banks
Mammalian Cell Banking Market Trends Shaping Long-Term Demand
Leading firms within the mammalian cell banking sector are concentrating on creating advanced solutions, including novel stable cell line systems, to boost cell line efficiency, maintain genetic consistency over extended periods, and optimize biopharmaceutical manufacturing workflows. These stable cell line systems consist of genetically modified mammalian cells engineered to reliably generate a specific protein or therapeutic compound across numerous generations, exhibiting excellent genetic stability and replicability. For example, in August 2024, WuXi Biologics, a biopharmaceutical company from China, introduced the WuXia293 Stable platform, which is an inventive HEK293-based stable cell line system tailored for the production and manufacturing of challenging-to-express biologic molecules. Employing proprietary mammalian cell line development technology, this platform guarantees consistent expression and uniform quality through prolonged cell passages. The WuXia293 Stable platform addresses issues like low yields and diminished quality typically encountered with conventional CHO cell systems, achieving this by providing high protein titers, enhanced human-like glycosylation, and scalable production suitable for both clinical and commercial manufacturing.
Mammalian Cell Banking Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the mammalian cell banking market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, Eurofins Scientific SE, Charles River Laboratories International Inc., Catalent Inc., Sartorius Stedim Biotech S A, Samsung Biologics Co Ltd, CMIC Holdings Co Ltd, WuXi Biologics Inc., Evotec SE, AGC Biologics Inc., GenScript ProBio Co Ltd, Syngene International Limited, KBI Biopharma Inc., Rentschler Biopharma SE, Polpharma Biologics S A, Abzena plc, 53Biologics, Cellistic, GBI Biomanufacturing, ABL Inc, OmniaBio, uBriGene Biosciences
View The Full Mammalian Cell Banking Market Report:
Mammalian Cell Banking Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the mammalian cell banking market in 2025. The regions covered in the mammalian cell banking market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.